---
title: "Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287643086.md"
description: "Hologic, Inc. and Biotheranostics, Inc. presented new data at ASCO 2026 highlighting the Breast Cancer Index® Test's influence on treatment decisions for early-stage HR+ breast cancer. The findings showed a significant increase of over 30% in recommendations for extended endocrine therapy based on BCI Test results, underscoring its importance in personalized treatment planning."
datetime: "2026-05-26T13:08:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287643086.md)
  - [en](https://longbridge.com/en/news/287643086.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287643086.md)
---

# Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions

Hologic, Inc. and Biotheranostics, Inc. unveiled new findings showcasing the impact of Breast Cancer Index® (BCI™) Test results on treatment decisions for patients with early-stage hormone receptor-positive (HR+) breast cancer. The data revealed a noteworthy shift in medical recommendations for extended endocrine therapy, with a surge of over 30% in suggestions for patients identified by the BCI Test as potentially benefiting from this approach. This emphasizes the test's valuable role in guiding personalized treatment plans for HR+ breast cancer patients.

### Related Stocks

- [HOLX.US](https://longbridge.com/en/quote/HOLX.US.md)

## Related News & Research

- [H&R Block (NYSE:HRB) Announces Quarterly Earnings Results, Beats Expectations By $0.17 EPS](https://longbridge.com/en/news/295581464.md)
- [MBX Biosciences posts corporate presentation on precision peptide programs for endocrine, metabolic diseases](https://longbridge.com/en/news/295105907.md)
- [Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | ATOS Stock News](https://longbridge.com/en/news/295237705.md)
- [Safe Harbor 401(k) plan wins Canopy HR endorsement for cannabis clients](https://longbridge.com/en/news/295105893.md)
- [Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update | IMNM Stock News](https://longbridge.com/en/news/295573212.md)